Search

Your search keyword '"Schaap N"' showing total 308 results
Start Over Author "Schaap N"
308 results on '"Schaap N"'

3. Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells

Author

Van der Meer, J. M. R., Maas, R. J. A., Guldevall, K., Klarenaar, K., De Jonge, P. K. J. D., Hoogstad-van Evert, J. S., van der Waart, A. B., Cany, J., Safrit, J. T., Lee, J. H., Wagena, E., Friedl, P., Önfelt, B., Massuger, L. F., Schaap, N. P. M., Jansen, J. H., Hobo, W., and Dolstra, H.

Published
2021
Full Text
View/download PDF

4. Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.

Author

de Jonge, P. K. J. D., van Hauten, P. M. M., Janssen, L. D., de Goede, A. L., Berrien-Elliott, M. M., van der Meer, J. M. R., Mousset, C. M., Roeven, M. W. H., Foster, M., Blijlevens, N., Hobo, W., Fehniger, T. A., Jansen, J. H., Schaap, N. P. M., and Dolstra, H.

Subjects
KILLER cells, ACUTE myeloid leukemia, CURRENT good manufacturing practices, ARYL hydrocarbon receptors, HEMATOPOIETIC stem cells
Abstract

Allogeneic natural killer (NK) cell-based immunotherapy is a promising, well-tolerated adjuvant therapeutic approach for acute myeloid leukemia (AML). For reproducible NK cell immunotherapy, a homogenous, pure and scalable NK cell product is preferred. Therefore, we developed a good manufacturing practice (GMP)-compliant, cytokine-based ex vivo manufacturing process for generating NK cells from CD34+ hematopoietic stem and progenitor cells (HSPC). This manufacturing process combines amongst others IL15 and IL12 and the aryl hydrocarbon receptor antagonist StemRegenin-1 (SR1) to generate a consistent and active NK cell product that fits the requirements for NK cell immunotherapy well. The cell culture protocol was first optimized to generate NK cells with required expansion and differentiation capacity in GMP-compliant closed system cell culture bags. In addition, phenotype, antitumor potency, proliferative and metabolic capacity were evaluated to characterize the HSPC-NK product. Subsequently, seven batches were manufactured for qualification of the process. All seven runs demonstrated consistent results for proliferation, differentiation and antitumor potency, and preliminary specifications for the investigational medicinal product for early clinical phase trials were set. This GMP-compliant manufacturing process for HSPC-NK cells (named RNK001 cells) is used to produce NK cell batches applied in the clinical trial 'Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL2 in patients with acute myeloid leukemia' approved by the Dutch Ethics Committee (EudraCT 2019-001929-27). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes

Author

Martino, R, Henseler, A, van Lint, M, Schaap, N, Finke, J, Beelen, D, Vigouroux, S, Alessandrino, E P, Mufti, G J, Veelken, J H, Bruno, B, Yakoub-Agha, I, Volin, L, Maertens, J, Or, R, Leblond, V, Rovira, M, Kalhs, P, Alvarez, A F, Vitek, A, Sierra, J, Wagner, E, Robin, M, de Witte, T, and Kröger, N

Published
2017
Full Text
View/download PDF

7. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Author

Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El-Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L, and Kröger, N

Published
2016
Full Text
View/download PDF

8. P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

Author

Kiladjian, J.-J., primary, Tefferi, A., additional, Passamonti, F., additional, Vannucchi, A., additional, Talpaz, M., additional, Cervantes, F., additional, Harrison, C. N., additional, Mesa, R. A., additional, Mascarenhas, J., additional, Schaap, N., additional, Verstovsek, S., additional, Devos, T., additional, Rose, S., additional, Zhang, J., additional, Sy, O., additional, and Pardanani, A., additional

Published
2022
Full Text
View/download PDF

9. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO-HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT

Author

Tilmont, R., primary, Yakoub-Agha, I., additional, Eikema, D.-J., additional, Zinger, N., additional, Haenel, M., additional, Schaap, N., additional, Herrera Arroyo, C., additional, Schuermans, C., additional, Bethge, W., additional, Engelhardt, M., additional, Kuball, J., additional, Michieli, M., additional, Schub, N., additional, Wilson, K. M. O., additional, Bourhis, J. H., additional, Mateos, M. V., additional, Robin, N., additional, Jost, E., additional, Kröger, N., additional, Moraleda, J. M., additional, Sica, S., additional, Hayden, P. J., additional, Beksac, M., additional, Schönland, S., additional, and Manier, S., additional

Published
2022
Full Text
View/download PDF

10. Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT

Author

Passweg, J R, Labopin, M, Cornelissen, J, Volin, L, Socié, G, Huynh, A, Tabrizi, R, Wu, D, Craddock, C, Schaap, N, Kuball, J, Chevallier, P, Cahn, J Y, Blaise, D, Ghavamzadeh, A, Bilger, K, Ciceri, F, Schmid, C, Giebel, S, Nagler, A, and Mohty, M

Published
2015
Full Text
View/download PDF

13. Haplotype motif-based models for KIR-genotype informed selection of hematopoietic cell donors fail to predict outcome of patients with Myelodysplastic Syndromes or secondary Acute Myeloid Leukemia (vol 11,& nbsp;584520, 2021)

Author

Schetelig, J., Baldauf, H., Koster, L., Kuxhausen, M., Heidenreich, F., Wreede, L.C. de, Spellman, S., Gelder, M. van, Bruno, B., Onida, F., Lange, V., Massalski, C., Potter, V., Ljungman, P., Schaap, N., Hayden, P., Lee, S.P.N.J., Kroeger, N., Hsu, K.T.Y., Schmidt, A.H., Yakoub-Agha, I., and Robin, M.

Subjects
KIR3DL1, unrelated donor, hematopoietic stem cell transplantation, donor selection, KIR2DS1, KIR
Published
2021

21. CONDITIONING INTENSITY IN MIDDLE AGED PATIENTS WITH AML IN CR1. NO ADVANTAGE FOR MYELOABLATIVE REGIMENS IRRESPECTIVE OF THE RISK GROUP. AN OBSERVATIONAL ANALYSIS BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT: PH-O148

Author

Passweg, J. R., Labopin, M., Cornelissen, J., Volin, L., Socié, G., Huynh, A., Tabrizi, R., Wu, D., Craddock, C., Schaap, N., Kuball, J., Chevallier, P., Cahn, J.-Y., Blaise, D., Ghavamzadeh, A., Bilger, K., Ciceri, F., Nagler, A., Schmid, C., Giebel, S., and Mohty, M.

Published
2014

22. REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA: A COMPARISON OF TANDEM AUTO-ALLOGRAFT TO EARLY REDUCED INTENSITY ALLOGRAFT AS UPFRONT TRANSPLANT: AN EBMT ANALYSIS ON BEHALF OF THE PLASMA CELL DISORDERS: PH-O144

Author

Sahebi, F., Iacobelli, S., Van Biezen, A., Volin, L., Dreger, P., Michallet, M., Ljungman, P. T., Morris, C. TCM, Schonland, S., de Witte, T., Garderet, L., Henseler, A., Schaap, N. P. M., López-Corral, L., Poire, X., Passweg, J., Hamljadi, R. M., Kroeger, N., and Gahrton, G.

Published
2014

24. IMPACT OF CYTOGENETIC USING THE IPSS REVISED CYTOGENETIC CLASSIFICATION ON OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR MDS OR AML EVOLVING FROM MDS: A RETROSPECTIVE MULTICENTER STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT: PH-O012

Author

Koenecke, C., Göhring, G., de Wreede, L., van Biezen, A., Scheid, C., Volin, L., Maertens, J., Finke, J., Schaap, N. P. M., Robin, M., Passweg, J., Cornelissen, J., Beelen, D., Heuser, M., de Witte, T., and Kröger, N.

Published
2014

28. Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission

Author

Diaz-Beya, M, Labopin, M, Maertens, J, Alijurf, M, Passweg, J, Dietrich, B, Schouten, H, Socie, G, Schaap, N, Schwerdtfeger, R, Volin, L, Michallet, M, Polge, E, Sierra, J, Mohty, M, Esteve, J, Nagler, A, and European Soc Blood Marrow

Subjects
surgical procedures, operative, AML, hemic and lymphatic diseases, 9) AML, DEK-NUP214, prognosis, t(6, allo-SCT
Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0 center dot 001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

Published
2020

30. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

Author

Van der Meer, J. M. R., primary, Maas, R. J. A., additional, Guldevall, K., additional, Klarenaar, K., additional, de Jonge, P. K. J. D., additional, Evert, J. S. Hoogstad-van, additional, van der Waart, A. B., additional, Cany, J., additional, Safrit, J. T., additional, Lee, J. H., additional, Wagena, E., additional, Friedl, P., additional, Önfelt, B., additional, Massuger, L. F., additional, Schaap, N. P. M., additional, Jansen, J. H., additional, Hobo, W., additional, and Dolstra, H., additional

Published
2020
Full Text
View/download PDF

40. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Onida, F., Wreede, L.C. de, Biezen, A. van, Eikema, D.J., Byrne, J.L., Iori, A.P., Schots, R., Jungova, A., Schetelig, J., Finke, J., Veelken, H., Johansson, J.E., Craddock, C., Stelljes, M., Theobald, M., Holler, E., Schanz, U., Schaap, N., Bittenbring, J., Olavarria, E., Chalandon, Y., Kroger, N., Chronic Malignancies Working Party, Laboratory of Molecullar and Cellular Therapy, and Clinical sciences

Subjects
Myeloid, Male, 0301 basic medicine, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], 0302 clinical medicine, Recurrence, Risk Factors, hemic and lymphatic diseases, Medicine, Chronic, ddc:616, Leukemia, Framingham Risk Score, Hematopoietic Stem Cell Transplantation/methods/mortality, Graft Survival, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Haematopoiesis, surgical procedures, operative, 030220 oncology & carcinogenesis, BCR-ABL Negative/mortality/therapy, Female, Homologous, Adult, medicine.medical_specialty, Allogeneic transplantation, Human leukocyte antigen, Malignancy, Disease-Free Survival, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, 03 medical and health sciences, Internal medicine, Humans, Transplantation, Homologous, Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN), Sibling, allogeneic transplantation, atypical chronic myeloid leukaemia, Myelodyslastic/Myeloproliferative Neoplasms (MDS/MPN), Ph-negative CML:BCR-ABL1-negative, Aged, Retrospective Studies, Transplantation, business.industry, Retrospective cohort study, atypical chronic myeloid leukaemia, medicine.disease, allogeneic transplantation, Surgery, Ph-negative CML: BCR-ABL1-negative, 030104 developmental biology, business, Atypical
Abstract

Contains fulltext : 175137.pdf (Publisher’s version ) (Closed access) Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%. A reduced intensity conditioning was employed in 24% of patients. T-cell depletion was applied in 87% and 26% of transplants from MUD and HLA-identical siblings, respectively. According to the EBMT risk-score, 45% of patients were 'low-risk', 31% 'intermediate-risk' and 24% 'high-risk'. Following allo-HSCT, 87% of patients achieved complete remission. At 5 years, relapse-free survival was 36% and non-relapse mortality (NRM) was 24%, while relapse occurred in 40%. Patient age and the EBMT score had an impact on overall survival. Relapse-free survival was higher in MUD than in HLA-identical sibling HSCT, with no difference in NRM. In conclusion, this study confirmed that allo-HSCT represents a valid strategy to achieve cure in a reasonable proportion of patients with aCML, with young patients with low EBMT risk score being the best candidates.

Published
2017

45. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT

Author

Schmid, C., Labopin, M., Schaap, N., Veelken, H., Schleuning, M., Stadler, M., Finke, J., Hurst, E., Baron, F., Ringden, O., Bug, G., Blaise, D., Tischer, J., Bloor, A., Esteve, J., Giebel, S., Savani, B., Gorin, N.C., Ciceri, F., Mohty, M., Nagler, A., EBMT Acute Leukaemia Working Party, Schmid, Christoph, Labopin, Myriam, Schaap, Nicolaa, Veelken, Hendrik, Schleuning, Michael, Stadler, Michael, Finke, Juergen, Hurst, Erin, Baron, Frederic, Ringden, Olle, Bug, Gesine, Blaise, Didier, Tischer, Johanna, Bloor, Adrian, Esteve, Jordi, Giebel, Sebastian, Savani, Bipin, Gorin, Norbert-Claude, Ciceri, Fabio, Mohty, Mohamad, and Nagler, Arnon

Subjects
acute leukaemia, Oncology, Adult, Male, medicine.medical_specialty, Allogeneic transplantation, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Relapse prevention, Donor lymphocyte infusion, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, allogeneic stem cell transplantation, Risk Factors, Internal medicine, medicine, Humans, Registries, Stage (cooking), relapse prevention, Aged, business.industry, Cytogenetics, Hematology, Middle Aged, Allografts, Tissue Donors, Transplantation, Leukemia, Myeloid, Acute, 030220 oncology & carcinogenesis, Lymphocyte Transfusion, Cohort, Female, Stem cell, DLI, business, 030215 immunology, Follow-Up Studies, Stem Cell Transplantation
Abstract

Strategies for relapse prevention after allogeneic transplantation in acute leukaemia are warranted. A registry-based matched-pair analysis evaluated the efficacy of prophylactic donor lymphocyte infusion (proDLI). Adults receiving proDLI in complete remission (CR) and controls were pair-matched for age, diagnosis, cytogenetics, stage, donor, gender, conditioning and T-cell depletion. Eighty-nine pairs were identified (median follow-up: 6.9years). Within the entire cohort, no difference was observed. However, among patients with high-risk acute myeloid leukaemia (AML) (unfavourable cytogenetics and/or transplanted beyond first CR), proDLI recipients had improved overall survival (69.8% vs. 40.2% in controls, P=0.027). ProDLI has moderate efficacy, but can contribute to improved outcome in high-risk AML.

Published
2018

46. PS1459 FEDRATINIB IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX): A REANALYSIS OF THE PHASE 2 JAKARTA-2 STUDY

Author

Harrison, C., primary, Schaap, N., additional, Vannucchi, A., additional, Kiladjian, J.-J., additional, Jourdan, E., additional, Silver, R., additional, Schouten, H., additional, Passamonti, F., additional, Zweegman, S., additional, Talpaz, M., additional, Verstovsek, S., additional, Gerike, T., additional, Rose, S., additional, Li, M., additional, Brownstein, C., additional, and Mesa, R., additional

Published
2019
Full Text
View/download PDF

47. Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Author

Auner, H, Iacobelli, S, Sbianchi, G, Knol-Bout, C, Blaise, D, Russell, N, Apperley, J, Pohlreich, D, Browne, P, Kobbe, G, Isaksson, C, Lenhoff, S, Scheid, C, Touzeau, C, Jantunen, E, Anagnostopoulos, A, Yakoub-Agha, I, Tanase, A, Schaap, N, Wiktor-Jedrzejczak, W, Krejci, M, Schönland, S, Morris, C, Garderet, L, and Kröger, N

Subjects
Adult, Male, Transplantation Conditioning, Immunology, Transplantation, Autologous, 1102 Cardiovascular Medicine And Haematology, Article, Plasma Cell Disorders, Settore MED/01 - Statistica Medica, Recurrence, immune system diseases, hemic and lymphatic diseases, Humans, cardiovascular diseases, neoplasms, Melphalan, Aged, Dose-Response Relationship, Drug, Hematopoietic Stem Cell Transplantation, Middle Aged, Survival Analysis, Treatment Outcome, surgical procedures, operative, Female, Multiple Myeloma, Stem Cell Transplantation
Abstract

Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m2 and melphalan 140 mg/m2 are equally effective and tolerable in clinically relevant patient subgroups we analyzed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, hematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 mg/m2 (n=245) and melphalan 200 mg/m2 (n=1719) groups. Multivariable subgroup analysis showed that disease status at transplantation interacted with overall survival, progression-free survival, and cumulative incidence of relapse, with a significant advantage associated with melphalan 200 mg/m2 in patients transplanted in less than partial response (adjusted hazard ratios for melphalan 200 mg/m2 versus melphalan 140 mg/m2: 0.5, 0.54, and 0.56). In contrast, transplantation in very good partial or complete response significantly favored melphalan 140 mg/m2 for overall survival (adjusted hazard ratio: 2.02). Age, renal function, prior proteasome inhibitor treatment, gender, or Karnofsky score did not interact with overall/progression-free survival or relapse rate in the melphalan dose groups. There were no significant survival or relapse rate differences between melphalan 200 mg/m2 and melphalan 140 mg/m2 patients with high-risk or standard-risk chromosomal abnormalities. In conclusion, remission status at the time of transplantation may favor the use of melphalan 200 mg/m2 or melphalan 140 mg/m2 for key transplant outcomes (NCT01362972).

Published
2017

48. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT

Author

Gelder, M. van, Ziagkos, D., Wreede, L. de, Biezen, A. van, Dreger, P., Gramatzki, M., Stelljes, M., Andersen, N.S., Schaap, N., Vitek, A., Beelen, D., Lindstrom, V., Finke, J., Passweg, J., Eder, M., Machaczka, M., Delgado, J., Kruger, W., Raida, L., Socie, G., Jindra, P., Afanasyev, B., Wagner, E., Chalandon, Y., Henseler, A., Schoenland, S., Kroger, N., Schetelig, J., CLL Subcomm Chronic Malignancies W, European Soc Blood Marrow Transpla, HUS Comprehensive Cancer Center, Clinicum, Department of Oncology, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Hematologie (9), and Interne Geneeskunde

Subjects
Male, Oncology, Cancer Research, Transplantation Conditioning, BLOOD, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], medicine.medical_treatment, Chronic lymphocytic leukemia, Medizin, MULTICENTER, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, THERAPY, chemistry.chemical_compound, 0302 clinical medicine, HLA Antigens, Risk Factors, IBRUTINIB, education.field_of_study, Hazard ratio, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Prognosis, RELAPSED CLL, Tissue Donors, EUROPEAN-SOCIETY, 3. Good health, Risk factor analysis, Treatment Outcome, 030220 oncology & carcinogenesis, Ibrutinib, SURVIVAL, Female, Refractory Chronic Lymphocytic Leukemia, Adult, medicine.medical_specialty, 3122 Cancers, Population, HLA-matched donor, MARROW TRANSPLANTATION, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Non-relapse mortality, Internal medicine, medicine, Humans, Transplantation, Homologous, education, Aged, Retrospective Studies, Chromosome Aberrations, business.industry, Kinase- and BCL2 inhibitor refractory, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, Confidence interval, Surgery, Transplantation, chemistry, MATCHED UNRELATED DONOR, del(17p), FOLLOW-UP, business, 030215 immunology
Abstract

Patients with chronic lymphocytic leukemia with del(17p) or del(11q) have poor long-term prognosis with targeted therapies. Conversely, this retrospective European Society for Blood and Marrow Transplantation registry study shows that young high cytogenetic risk responsive patients with human leukocyte antigen-matched donors have a high 8-year progression-free survival and low 2-year non-relapse mortality after allogeneic stem cell transplantation. This treatment then may compare favorably with targeted therapies for younger high cytogenetic risk patients.Background: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase-and BCL2-inhibitors (KI, BCL2i). Allogeneic hematopoietic stem cell transplantation (alloHCT) may result in sustained PFS, especially in younger patients because of its age-dependent non-relapse mortality (NRM) risk, but outcome data are lacking for this population. Patients and Methods: Risk factors for 2-year NRM and 8-year PFS were identified in patients

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results